Prevention of colorectal cancer in patients with inflammatory bowel disease


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Patients with inflammatory bowel disease (IBD) have an increased risk of colorectal cancer (CRC), which necessitates regular screening for colonic epithelial dysplasia. The pathophysiology of IBD-associated colorectal cancer is reduced to the carcinogenic effect of inflammation. This review describes the epidemiology and pathophysiology of IBD-associated CRC. The strategy of managing IBD patients with the aim of detecting dysplasia in the early stages and preventing colorectal cancer from the standpoint of domestic and foreign clinical guidelines of leading medical communities is considered in detail. The literature search was carried out in PubMed and Google Scholar systems using the keywords: ulcerative colitis, Crohn's disease, colorectal cancer, pathophysiology, genetic predisposition, microbiota, risk factors, screening, recommendations. We have focused on clinical guidelines and studies published over the past years, and offer their review to general practitioners, gastroenterologists and coloproctologists for use in daily practice.

Full Text

Restricted Access

About the authors

G. R Bikbavova

Omsk State Medical University

Email: galiya1976@mail.ru
Omsk, Russia

M. A Livzan

Omsk State Medical University

Omsk, Russia

M. M Fedorin

Omsk State Medical University

Omsk, Russia

References

  1. Schmidt A., Weber O.F In memoriam of Rudolf virchow: a historical retrospective including aspects of inflammation, infection and neoplasia. Contrib Microbiol. 2006;13:1-15. doi: 10.1159/000092961.
  2. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30. doi: 10.3322/caac.21332.
  3. Ullman T.A, Itzkowitz S.H. Intestinal inflammation and cancer. Gastroenterology. 2011;140(6):1807-16. doi: 10.1053/j.gastro.2011.01.057.
  4. Chouhan H, Ferrandon S., Devecchio J., et al. A Changing Spectrum of Colorectal Cancer Biology with Age: Implications for the Young Patient. Dis Colon Rectum. 2019;62(1):21-6. Doi: 10.1097/ DCR.0000000000001188.
  5. Van Der Kraak L., Gros P, Beauchemin N. Colitis-associated colon cancer: Is it in your genes?. World J Gastroenterol. 2015;21(41):11688-99. doi: 10.3748/wjg.v21.i41.11688.
  6. Keller D.S., Windsor A., Cohen R., et al. Colorectal cancer in inflammatory bowel disease: review of the evidence. Tech Coloproctol. 2019;23(1):3-13. doi: 10.1007/s10151-019-1926-2.
  7. Brentnall T.A, Crispin D.A., Rabinovitch P.S., et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology. 1994;107(2):369-78. doi: 10.1016/0016-5085(94)90161-9.
  8. Колодей Е.Н. Язвенный колит и рак толстой кишки: актуальные и нерешенные вопросы диагностики. Медицинский альманах. 2013;1(25):74-8.
  9. Gao T, Hu Q, Hu X., et al. Novel selective TOPK http://www.tsatu.edu.ua/nauka/n/aspirantura-ta-doktorantura/documents/shablony-blanky/
  10. Bezzio C., Festa S., Saibeni S., et al. Chemoprevention of colorectal cancer in ulcerative colitis: digging deep in current evidence. Expert Rev Gastroenterol Hepatol. 2017;11(4):339-47. doi: 10.1080/17474124.2017.1292129.
  11. Dirisina R., Katzman R.B., Goretsky T., et al. p53 and PUMA independently regulate apoptosis of intestinal epithelial cells in patients and mice with colitis. Gastroenterology. 2011;141(3):1036-45. doi: 10.1053/j.gastro.2011.05.032.
  12. Ливзан М.А., Макейкина М.А. Неспецифический язвенный колит: генетика иммунного ответа. Клинические перспективы гастроэнтерологии, гепатологии. 2012;1:28-33.
  13. Westbrook A.M., Szakmary A., Schiestl R.H. Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models. Mutat Res. 2010;705(1):40-59. doi: 10.1016/j.mrrev.2010.03.001.
  14. Goel G.A., Kandiel A., Achkar J.P, et al. Molecular pathways underlying IBD-associated colorectal neoplasia: therapeutic implications. Am J Gastroenterol. 2011;106(4):719-30. doi: 10.1038/ajg.2011.51.
  15. Beaugerie L., Itzkowitz S.H. Cancers complicating inflammatory bowel disease. N Engl J Med. 2015;372(15):1441-52. Doi: 10.1056/ NEJMra1403718.
  16. Kang M., Martin A. Microbiome and colorectal cancer: Unraveling host-microbiota interactions in colitis-associated colorectal cancer development.
  17. McCoy A.N., Araujo-Perez F, Azcarate-Peril A., et al. Fusobacterium is associated with colorectal adenomas. PloS One. 2013;8(1):e53653. doi: 10.1371/journal.pone.0053653.
  18. Khan A.A., Khan Z., Malik A., et al. Colorectal cancer-inflammatory bowel disease nexus and felony of Escherichia coli. Life Sci. 2017;180:60-7. doi: 10.1016/j.lfs.2017.05.016.
  19. Eaden J.A., Abrams K.R., Mayberry J.F. The risk of colorectal cancer in ulcerative colitis: a metaanalysis. Gut. 2001;48(4):526-35. Doi: 10.1136/ gut.48.4.526.
  20. von Roon A.C., Reese G., Teare J. The risk of cancer in patients with Crohn's disease. Dis Colon Rectum. 2007;50(6):839-55. doi: 10.1007/s10350-006-0848-z.
  21. Jess T, Rungoe C., Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a metaanalysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10(6):639-45. doi: 10.1016/j.cgh.2012.01.010.
  22. Jewel Samadder N., Valentine J.F, Guthery S., et al. Colorectal Cancer in Inflammatory Bowel Diseases: A Population-Based Study in Utah. Dig Dis Sci. 2017;62(8):2126-32. doi: 10.1007/s10620-016-4435-4.
  23. Fornaro R., Caratto M., Caratto E., et al. Colorectal Cancer in Patients With Inflammatory Bowel Disease: The Need for a Real Surveillance Program. Clin Colorectal Cancer. 2016;15(3):204-12. doi: 10.1016/j.clcc.2016.02.002.
  24. Nyboe Andersen N., Pasternak B., Basit S., et al. Association between tumor necrosis factor-antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014;311 (23):2406-13. Doi: 10.1001/ jama.2014.5613.
  25. Marley A.R., Nan H. Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet. 2016; 7(3):105-14.
  26. Askling J., Dickman P.W., Karlen P, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology. 2001;120(6):1356-62. Doi: 10.1053/ gast.2001.24052
  27. Ивашкин В.Т, Шелыгин Ю.А., Халиф И.Л. и др. Клинические рекомендации Российской Гастроэнтерологической Ассоциации и Ассоциации Колопроктологов России по диагностике и лечению язвенного колита. Колопроктология. 2017;1(59):6-30.
  28. American Society for Gastrointestinal Endoscopy Standards of Practice Committee, Shergill A.K., Lightdale J.R., Bruining D.H., et al. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc. 2015;81(5):1101-21.e1-13. doi: 10.1016/j.gie.2014.10.030.
  29. Annese V, Daperno M., RutterM.D. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7(12):982-1018. doi: 10.1016/j.crohns.2013.09.016.
  30. Rex D.K., Boland C.R., Dominitz J.A., et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017;153( 1):307-23. Doi: 10.1053/j. gastro.2017.05.013.
  31. Rubin D.T, Ananthakrishnan A.N., Siegel C.A., et al. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114(3):384-413. doi: 10.14309/ajg.0000000000000152.
  32. Farraye F.A., Odze R.D., Eaden J., et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138(2):746-74, 774.e1-4; quiz e12-3. Doi: 10.1053/j. gastro.2009.12.035.
  33. Cairns S.R., Scholefield J.H., Steele R.J., et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59(5):666-89. doi: 10.1136/gut.2009.179804.
  34. Magro F., Gionchetti P, Eliakim R., et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11(6):649-70. doi: 10.1093/ecco-jcc/jjx008.
  35. Куваев Р, Кашин С., Завьялов Д. Роль колоно-скопии в диагностике дисплазии и рака толстой кишки при язвенном колите. Врач. 2016;2:70-6.
  36. Baker A.M., Cross W., Curtius K., et al. Evolutionary history of human colitis-associated colorectal cancer. Gut. 2019;68(6):985-95. Doi: 10.1136/ gutjnl-2018-316191.
  37. Berg D.R., Colombel J.F., Ungaro R. The Role of Early Biologic Therapy in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019;25(12):1896-1905. doi: 10.1093/ibd/izz059.
  38. Abdalla L.F., Chaudhry Ehsanullah R., Karim F, et al. Role of Using Nonsteroidal Anti-Inflammatory Drugs in Chemoprevention of Colon Cancer in Patients With Inflammatory Bowel Disease. Cureus. 2020;12(5):e8240. doi: 10.7759/cureus.8240.
  39. Nadeem M.S., Kumar V., Al-Abbasi F.A., et al. Risk of colorectal cancer in inflammatory bowel diseases. Semin Cancer Biol. 2020;64:51-60. Doi: 10.1016/j. semcancer.2019.05.001.
  40. Nagarjun S., Dhadde S.B., Veerapur V.P., et al. Ameliorative effect of chromium-d-phenylalanine complex on indomethacin-induced inflammatory bowel disease in rats. Biomed Pharmacother. 2017;89:1061-66. Doi: 10.1016/j. biopha.2017.02.042.
  41. Dobrzycka M., Spychalski P, tachihski A.J., et al. Statins and Colorectal Cancer - A Systematic Review. Exp Clin Endocrinol Diabetes. 2020;128(4):255-62. doi: 10.1055/a-0668-5692.
  42. Ehrlich A.C., Patel S., Meillier A., et al. Chemoprevention of colorectal cancer in inflammatory bowel disease. Expert Rev Anticancer Ther. 2017;17(3):247-255. doi: 10.1080/14737140.2017.1283987.
  43. Dai C., Jiang M., Sun M.J. Statins and the Risk of Inflammatory Bowel Disease. Am J Gastroenterol. 2016;111(12):1851. doi: 10.1038/ajg.2016.412.
  44. Генкель В.В., Шапошник И.И. Воспалительные заболевания кишечника и статины. Российский журнал гастроэнтерологии, гепатологии, коло-проктологии. 2020;30(1):7-13.
  45. Cohen-Mekelburg S., Schneider Y., Gold S., et al. Risk of Early Colorectal Cancers Needs to Be Considered in Inflammatory Bowel Disease Care. Digestive Diseases and Sciences. 2019;64(8):22 73- 79. Doi: 10.1007/ s10620-019-05554-1.
  46. Ливзан М.А., Макейкина М.А. Воспалительные заболевания кишечника: современные аспекты диагностики и лечения. Consilium Medicum. Гастроэнтерология. 2010;2:60-5.
  47. Terdiman J.P, Steinbuch M., Blumentals W.A., et al. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13(4):367-71. doi: 10.1002/ibd.20074.
  48. Velayos F.S., Loftus E.V. Jr, Jess T., et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology. 2006;130(7):1941-49. doi: 10.1053/j.gastro. 2006.03.028.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies